LALPATHLAB Stock Overview
Engages in the operation of laboratories for carrying out pathological investigations in India and internationally.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 3/6 |
Past Performance | 5/6 |
Financial Health | 5/6 |
Dividends | 3/6 |
Dr. Lal PathLabs Limited Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | ₹2,647.85 |
52 Week High | ₹2,767.10 |
52 Week Low | ₹1,916.05 |
Beta | 0.28 |
1 Month Change | 14.21% |
3 Month Change | 16.38% |
1 Year Change | 31.39% |
3 Year Change | -7.68% |
5 Year Change | 156.57% |
Change since IPO | 220.95% |
Recent News & Updates
Recent updates
We Think Dr. Lal PathLabs' (NSE:LALPATHLAB) Profit Is Only A Baseline For What They Can Achieve
May 21What Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) P/E Is Not Telling You
May 01Be Wary Of Dr. Lal PathLabs (NSE:LALPATHLAB) And Its Returns On Capital
Apr 13These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Safely
Mar 06Dr. Lal PathLabs Limited Just Missed EPS By 5.4%: Here's What Analysts Think Will Happen Next
Feb 04Subdued Growth No Barrier To Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) Price
Dec 28Is Dr. Lal PathLabs (NSE:LALPATHLAB) Using Too Much Debt?
Nov 17Dr. Lal PathLabs (NSE:LALPATHLAB) Will Be Hoping To Turn Its Returns On Capital Around
Oct 12Here's Why Dr. Lal PathLabs (NSE:LALPATHLAB) Can Manage Its Debt Responsibly
Jul 07Be Wary Of Dr. Lal PathLabs (NSE:LALPATHLAB) And Its Returns On Capital
Jun 10Dr. Lal PathLabs (NSE:LALPATHLAB) Could Be Struggling To Allocate Capital
Feb 13Is Dr. Lal PathLabs (NSE:LALPATHLAB) Using Too Much Debt?
Dec 29Dr. Lal PathLabs (NSE:LALPATHLAB) Will Want To Turn Around Its Return Trends
Sep 21These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Reasonably Well
Sep 01Dr. Lal PathLabs (NSE:LALPATHLAB) Will Pay A Dividend Of ₹6.00
Jul 31Be Wary Of Dr. Lal PathLabs (NSE:LALPATHLAB) And Its Returns On Capital
Jun 23Does This Valuation Of Dr. Lal PathLabs Limited (NSE:LALPATHLAB) Imply Investors Are Overpaying?
Jun 11These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Safely
May 25Do Dr. Lal PathLabs's (NSE:LALPATHLAB) Earnings Warrant Your Attention?
Apr 28Is Dr. Lal PathLabs (NSE:LALPATHLAB) A Risky Investment?
Feb 17With EPS Growth And More, Dr. Lal PathLabs (NSE:LALPATHLAB) Is Interesting
Jan 20Shareholder Returns
LALPATHLAB | IN Healthcare | IN Market | |
---|---|---|---|
7D | 0.8% | -1.4% | -1.9% |
1Y | 31.4% | 39.8% | 41.0% |
Return vs Industry: LALPATHLAB underperformed the Indian Healthcare industry which returned 39.8% over the past year.
Return vs Market: LALPATHLAB underperformed the Indian Market which returned 41% over the past year.
Price Volatility
LALPATHLAB volatility | |
---|---|
LALPATHLAB Average Weekly Movement | 4.7% |
Healthcare Industry Average Movement | 5.8% |
Market Average Movement | 6.4% |
10% most volatile stocks in IN Market | 9.5% |
10% least volatile stocks in IN Market | 4.2% |
Stable Share Price: LALPATHLAB has not had significant price volatility in the past 3 months.
Volatility Over Time: LALPATHLAB's weekly volatility (5%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1949 | 4,048 | Shankha Banerjee | www.lalpathlabs.com |
Dr. Lal PathLabs Limited engages in the operation of laboratories for carrying out pathological investigations in India and internationally. The company provides pathological investigations of various branches of bio-chemistry, hematology, histopathology, microbiology, electrophoresis, immuno-chemistry, immunology, virology, cytology, and other pathological and radiological investigations. It also offers training programs.
Dr. Lal PathLabs Limited Fundamentals Summary
LALPATHLAB fundamental statistics | |
---|---|
Market cap | ₹219.91b |
Earnings (TTM) | ₹3.58b |
Revenue (TTM) | ₹22.27b |
61.5x
P/E Ratio9.9x
P/S RatioIs LALPATHLAB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
LALPATHLAB income statement (TTM) | |
---|---|
Revenue | ₹22.27b |
Cost of Revenue | ₹8.76b |
Gross Profit | ₹13.51b |
Other Expenses | ₹9.93b |
Earnings | ₹3.58b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 43.07 |
Gross Margin | 60.66% |
Net Profit Margin | 16.06% |
Debt/Equity Ratio | 4.4% |
How did LALPATHLAB perform over the long term?
See historical performance and comparisonDividends
0.9%
Current Dividend Yield56%
Payout RatioDoes LALPATHLAB pay a reliable dividends?
See LALPATHLAB dividend history and benchmarksDr. Lal PathLabs dividend dates | |
---|---|
Ex Dividend Date | Jun 10 2024 |
Dividend Pay Date | Jul 29 2024 |
Days until Ex dividend | 7 days |
Days until Dividend pay date | 56 days |
Does LALPATHLAB pay a reliable dividends?
See LALPATHLAB dividend history and benchmarks